Targeting the proteasome as a therapeutic strategy against haematological malignancies

Bibliography

• CIECHANOVER A: Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat. Rev. Mol. Cell. Biol. (2005) 6(1):79-87.
   PubMed Web of Science ®Google Scholar
• ORLOWSKI M, WILK S: Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex. Arch. Biochem. Biophys. (2000) 383(1):1-16.
   PubMed Web of Science ®Google Scholar
• VOORHEES PM, DEES EC, O’NEIL B, ORLOWSKI RZ: The proteasome as a target for cancer therapy. Clin. Cancer Res. (2003) 9(17):6316-6325.
   PubMed Web of Science ®Google Scholar
• YANG HH, MA MH, VESCIO RA, BERENSON JR: Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis. J. Clin. Oncol. (2003) 21(22):4239-4247.
   PubMed Web of Science ®Google Scholar
• RAJKUMAR SV, RICHARDSON PG, HIDESHIMA T, ANDERSON KC: Proteasome inhibition as a novel therapeutic target in human cancer. J. Clin. Oncol. (2005) 23(3):630-639.
   PubMed Web of Science ®Google Scholar
• VINITSKY A, MICHAUD C, POWERS JC, ORLOWSKI M: Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry (1992) 31(39):9421-9428.
   PubMed Web of Science ®Google Scholar
• ADAMS J, BEHNKE M, CHEN S et al.: Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg. Med. Chem. Lett. (1998) 8(4):333-338.
   PubMed Web of Science ®Google Scholar
• ADAMS J, PALOMBELLA, VJ, SAUSVILLE EA et al.: Proteasome inhibitors: A novel class of potent and effective anti-tumor agents. Cancer Res. (1999) 59(11):2615-2622.
   PubMed Web of Science ®Google Scholar
• AGHAJANIAN C, SOIGNET S, DIZON DS et al.: A Phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. (2002) 8(8):2505-2511.
   PubMed Web of Science ®Google Scholar
• ORLOWSKI RZ, STINCHCOMBE TE, MITCHELL B et al.: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. (2002) 20(22):4420-4427.
   PubMed Web of Science ®Google Scholar
• CORTES J, THOMAS D, KOLLER C et al.: Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin. Cancer Res. (2004) 10(10):3371-3376.
   PubMed Web of Science ®Google Scholar
• DY GK, THOMAS JP, WILDING G et al.: A Phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, Velcade®), in patients with advanced cancer. Clin. Cancer Res. (2005) 11(9):3410-3416.
   PubMed Web of Science ®Google Scholar
• PAPANDREOU CN, DALIANI DD, NIX D et al.: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J. Clin. Oncol. (2004) 22(11):2108-2121.
   PubMed Web of Science ®Google Scholar
• BLANEY SM, BERNSTEIN M, NEVILLE K et al.: Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children’s Oncology Group study (ADVL0015). J. Clin. Oncol. (2004) 22(23):4804-4809.
   PubMed Web of Science ®Google Scholar
• LIGHTCAP ES, McCORMACK TA, PIEN CS et al.: Proteasome inhibition measurements: clinical application. Clin. Chem. (2000) 46(5):673-683.
   PubMed Web of Science ®Google Scholar
• HIDESHIMA T, RICHARDSON P, CHAUHAN D et al.: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. (2001) 61(7):3071-3076.
   PubMed Web of Science ®Google Scholar
• RICHARDSON PG, BARLOGIE B, BERENSON J et al.: A Phase II study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. (2003) 348(26):2609-2617.
   PubMed Web of Science ®Google Scholar
• JAGANNATH S, BARLOGIE B, BERENSON J et al.: A Phase II study of two doses of bortezomib in relapsed or refractory myeloma. Br. J. Haematol. (2004) 127(2):165-172.
   PubMed Web of Science ®Google Scholar
• BLADÉ J, SAMSON D, REECE D et al.: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br. J. Haematol. (1998) 102(5):1115-1123.
   PubMed Web of Science ®Google Scholar
• RICHARDSON PG, BARLOGIE B, BERENSON J et al.: Survival, duration of response, and time to progression with bortezomib in patients with relapsed and refractory multiple myeloma: An update with additional follow-up. Hematol. J. (2004) 5(s2):S103 (Abstract 304).
   PubMedGoogle Scholar
• LUDWIG H, ZOJER N, ACKERMANN J et al.: Bortezomib induces remissions in patients with relapsed/refractory myeloma independent of their cytogenetic risk profile and addition of dexamethasone or dexamethasone plus chemotherapy can restore responsiveness. Haematologica (2005) 90(s1):147 (Abstract 722).
   Google Scholar
• RICHARDSON PG, SONNEVELD P, SCHUSTER MW et al.: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. (2005) 352(24):2487-2498.
   PubMed Web of Science ®Google Scholar
• MA MH, YANG HH, PARKER K et al.: The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin. Cancer Res. (2003) 9(3):1136-1144.
   PubMed Web of Science ®Google Scholar
• MITSIADES N, MITSIADES CS, RICHARDSON PG et al.: The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood (2003) 101(6):2377-2380.
   PubMed Web of Science ®Google Scholar
• SMALL GW, SOMASUNDARAM S, MOORE DT et al.: Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an anti-apoptotic role. Mol. Pharmacol. (2004) 66(6):1478-1490.
   PubMed Web of Science ®Google Scholar
• MITSIADES N, MITSIADES CS, POULAKI V et al.: Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl. Acad. Sci. USA (2002) 99(22):14374-14379.
   PubMed Web of Science ®Google Scholar
• MITSIADES N, MITSIADES CS, POULAKI V et al.: Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood (2002) 99(12):4525-4530.
   Google Scholar
• BERENSON JR, YANG HH, SWIFT R et al.: Bortezomib in combination with melphalan in the treatment of relapsed or refractory multiple myeloma: a Phase I/II study. Haematologica (2005) 90(s1):150 (Abstract 728).
   Google Scholar
• POPAT R, OAKERVEE H, AGRAWAL S et al.: Bortezomib and intravenous melphalan for relapsed multiple myeloma. Haematologica (2005) 90(s1):151 (Abstract 729).
   Google Scholar
• ORLOWSKI RZ, VOORHEES PM, GARCIA RA et al.: Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood (2005) 105(8):3058-3065.
   Google Scholar
• HOLLMIG K, STOVER J, TALAMO G et al.: Bortezomib (Velcade®) + Adriamycin™ + thalidomide + dexamethasone (VATD) as an effective regimen in patients with refractory or relapsed multiple myeloma. Blood (2004) 104(11):659a (Abstract 2399).
   Google Scholar
• ZANGARI M, BARLOGIE B, HOLLMIG K et al.: Marked activity of VELCADE® plus thalidomide (V+T) in advanced and refractory multiple myeloma. Blood (2004) 104(11):413a (Abstract 1480).
   Google Scholar
• RICHARDSON PG, SCHLOSSMAN R, MUNSHI N et al.: Phase I study of the safety and efficacy of bortezomib (Velcade®) in combination with CC-5013 (Revlimid™) in relapsed and refractory multiple myeloma (MM): the RevVel study. Haematologica (2005) 90(s1):26 (Abstract PL 5.04).
   Google Scholar
• CHANAN-KHAN A, ALSINA M, CARROLL M et al.: Dose escalating trial of 17-AAG with bortezomib (BZ) in patients with relapsed refractory multiple myeloma (MM). J. Clin. Oncol. (2005) 24(16S):605s (Abstract 6682).
   Web of Science ®Google Scholar
• KROPFF MH, BISPING G, WENNING D et al.: Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk. Res. (2005) 29(5):587-590.
   PubMed Web of Science ®Google Scholar
• CHANAN-KHAN A, MILLER KC, DiMICELI LA et al.: Velcade®, Doxil®, and low-dose thalidomide as salvage regimen for patients with relapsed or refractory multiple myeloma and Waldenströms macroglobulinemia: preliminary results of a Phase II study. Haematologica (2005) 90(s1):151 (Abstract 731).
   Google Scholar
• RICHARDSON PG, CHANAN-KHAN A, SCHLOSSMAN RL et al.: Phase II trial of single agent bortezomib (Velcade®) in patients with previously untreated multiple myeloma. Blood (2004) 104(11):100a (Abstract 336).
   PubMed Web of Science ®Google Scholar
• JAGANNATH S, DURIE BG, WOLF J et al.: Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br. J. Haematol. (2005) 129(6):776-783.
   PubMed Web of Science ®Google Scholar
• HAROUSSEAU J, ATTAL M, COITEUX V et al.: Bortezomib (Velcade®) plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: preliminary results of an IFM Phase II study. J. Clin. Oncol. (2005) 23(16S):598s (Abstract 6653).
   Google Scholar
• ORLOWSKI RZ, PETERSON BL, CALIGIURI MA et al.: Bortezomib and pegylated liposomal doxorubicin as initial therapy for adult patients with symptomatic multiple myeloma: CALGB study 10301. Haematologica (2005) 90(s1):151 (Abstract 730).
   Google Scholar
• OAKERVEE HE, POPAT R, CURRY N et al.: PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br. J. Haematol. (2005) 129(6):755-762.
   PubMed Web of Science ®Google Scholar
• ALEXANIAN R, WANG LM, WEBER DM, DE LASALLE KB: VTD (Velcade®, thalidomide, dexamethasone) as primary therapy for newly-diagnosed multiple myeloma. Blood (2004) 104(11):64a (Abstract 210).
   Google Scholar
• BARLOGIE B, HOLLMIG K, ZANGARI M et al.: Total therapy 3 (TT 3) for newly diagnosed myeloma, incorporating Velcade® into remission induction with DTPACE: early results regarding efficacy, PBSC mobilization and toxicities. Blood (2004) 104(11):156a (Abstract 538).
   Google Scholar
• MATEOS MV, BLADÉ J, DIAZ MEDIAVILLA J et al.: A Phase I/II national, multi-center, open-label study of bortezomib plus melphalan and prednisone (V-MP) in elderly untreated multiple myeloma patients. Blood (2004) 104(11):943a (Abstract 3462).
   Google Scholar
• JAGANNATH S, BARLOGIE B, BERENSON JR et al.: Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer (2005) 103(6):1195-1200.
   Google Scholar
• MOHRBACHER A, LEVINE AM: Reversal of advanced renal dysfunction on bortezomib treatment in multiple myeloma patients. J. Clin. Oncol. (2005) 23(16S):612s (Abstract 6714).
   Web of Science ®Google Scholar
• FASSAS AB, TRICOT G: Chromosome 13 deletion/hypodiploidy and prognosis in multiple myeloma patients. Leuk. Lymphoma (2004) 45(6):1083-1091.
   PubMed Web of Science ®Google Scholar
• JAGANNATH S, RICHARDSON PG, SONNEVELD P et al.: Bortezomib appears to overcome poor prognosis conferred by chromosome 13 deletion in Phase II and III trials. J. Clin. Oncol. (2005) 24(16S):560s (Abstract 6501).
   Google Scholar
• LONIAL S, WALLER EK, RICHARDSON PG et al.: Bortezomib-associated transient and cyclical thrombocytopenia: evidence for lack of marrow cytotoxicity. J. Clin. Oncol. (2005) 23(16S):587s (Abstract 6610).
   Google Scholar
• RICHARDSON PG, BRIEMBERG H, JAGANNATH S et al.: Peripheral neuropathy following bortezomib (VELCADE®, formerly PS-341) therapy in patients with advanced multiple myeloma (MM): characterization and reversibility. Blood (2003) 102(11):149a (Abstract 512).
   Google Scholar
• ESPARÍS-OGANDO A, ALEGRE A, AGUADO B et al.: Bortezomib is an efficient agent in plasma cell leukemias. Int. J. Cancer (2005) 114(4):665-667.
   PubMed Web of Science ®Google Scholar
• ALEGRE A, AGUADO B, LAHUERTA JJ et al.: Efficacy of bortezomib (VELCADE®) on plasma cell leukemias: clinical results in three patients. Haematologica (2005) 90(s1):152 (Abstract 733).
   Google Scholar
• MORRIS TCM, KETTLE P, FINNEGAN D et al.: Bortezomib is effective in plasma cell leukemia. Haematologica (2005) 90(s1):153 (Abstract 734).
   PubMedGoogle Scholar
• FOUILLARD L, GARDERET L, AZIZI L et al.: Multiple plasmacytomas successfully treated by VELCADE®. Haematologica (2005) 90(s1):153 (Abstract 735).
   Google Scholar
• CHIM CS, OOI GC, LOONG F et al.: Side effects and good effects from new chemotherapeutic agents. Case 3. Bortezomib in primary refractory plasmacytoma. J. Clin. Oncol. (2005) 23(10):2426-2428.
   PubMed Web of Science ®Google Scholar
• O’CONNOR OA, WRIGHT J, MOSKOWITZ C et al.: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J. Clin. Oncol. (2005) 23(4):676-684.
   PubMed Web of Science ®Google Scholar
• GOY A, YOUNES A, McLAUGHLIN P et al.: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin’s lymphoma. J. Clin. Oncol. (2005) 23(4):667-675.
   PubMed Web of Science ®Google Scholar
• BELCH A, KOUROUKIS CT, CRUMP M et al.: Phase II trial of bortezomib in mantle cell lymphoma. Blood (2004) 104(11):175a (Abstract 608).
   Google Scholar
• GOY A, BERNSTEIN S, KAHL B et al.: Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): preliminary results of the PINNACLE study. J. Clin. Oncol. (2005) 23(16S):575s (Abstract 6563).
   Google Scholar
• DUNLEAVY K, JANIK J, GEA-BANACLOCHE J et al.: Phase I/II study of bortezomib alone and bortezomib with dose-adjusted EPOCH chemotherapy in relapsed or refractory aggressive B-cell lymphoma. Blood (2004) 104(11):389a (Abstract 1385).
   Google Scholar
• ATTAR EC, DE ANGELO DJ, BALLEN K et al.: Phase I dose escalating trial of bortezomib (VELCADE®) in combination with idarubicin and cytarabine in patients with acute myeloid leukemia. Blood (2004) 104(11):498a (Abstract 1799).
   Google Scholar
• CORTES J, GILES F, O’BRIEN S et al.: Phase II study of bortezomib (VELCADE®, formerly PS-341) for patients with imatinib-refractory chronic myeloid leukemia (CML) in chronic (CP) or accelerated phase (AP). Blood (2003) 102(11):312b (Abstract 4971).
   Google Scholar
• FADERL S, RAI KR, GRIBBEN J et al.: Phase II study of three doses of single agent bortezomib in patients with fludarabine-refractory B-cell CLL. Blood (2004) 104(11):293b (Abstract 4841).
   Google Scholar
• KOC ON, BAHLIS NJ, LIU L et al.: A Phase I trial of bortezomib in combination with fludarabine in patients with lymphoproliferative neoplasms. J. Clin. Oncol. (2005) 23(16S):596s (Abstract 6647).
   Google Scholar
• STRAUSS SJ, MAHARAJ L, STEC J et al.: Phase II clinical study of bortezomib (VELCADE®) in patients (pts) with relapsed/refractory non-Hodgkin’s lymphoma (NHL) and Hodgkin’s disease (HD). Blood (2004) 104(11):389a (Abstract 1386).
   PubMedGoogle Scholar
• CHEN CI, WHITE D, KOUROUKIS CT et al.: Anti-tumor activity of bortezomib (PS-341; VELCADE®) in a Phase II study of patients with previously untreated or treated Waldenström’s macroglobulinemia (WM). Blood (2004) 104(11):896a (Abstract 3278).
   Google Scholar
• YOUNES A, PRO B, ROMAGUERA J, DANG N: Safety and efficacy of bortezomib (VELCADE®) for the treatment of relapsed classical Hodgkin’s disease. Blood (2004) 104(11):722a (Abstract 2638).
   Google Scholar
• KUMAR SK, THERNEAU TM, GERTZ MA et al.: Clinical course of patients with relapsed multiple myeloma. Mayo Clin. Proc. (2004) 79(7):867-874.
   PubMed Web of Science ®Google Scholar
• CHAUHAN D, CATLEY L, LI G et al.: A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cell (2005) 8(5):407-419.
   PubMed Web of Science ®Google Scholar
• KUHN DJ, VOORHEES PM, STRADER JS et al.: Potent activity of a novel, irreversible inhibitor of the ubiquitin-proteasome pathway against pre-clinical models of multiple myeloma. Blood (2005) 106(11):452a (Abstract 1576).
   Google Scholar
• ORLOWSKI RZ, KUHN DJ, SMALL GW et al.: Identification of novel inhibitors that specifically target the immunoproteasome, and selectively induce apoptosis in multiple myeloma and other immunoproteasome-expressing model systems. Blood (2005) 106(11):452a (Abstract 248).
   Google Scholar